The COVID-19 pandemic has brought the world to its knees, preventing many events from taking place and closing the doors of uncountable businesses. People across the world were advised to stay inside and only leave the house for necessities. At first it was strange, uncomfortable, and scary. As time moved…...
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
SAN DIEGO, June 24, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) and the National Foundation for Cancer…...
First-in-Class Drug Candidate Developed Through National Foundation for Cancer Research Funding Commences International Phase IIB Liver Cancer Clinical Trial
FOR IMMEDIATE RELEASE: May 19, 2020 CONTACT: National Foundation for Cancer Research Bradley Gillenwater, Senior Director for Global Program Development E-mail: bgillenwater@nfcr.org / Phone: 301-961-9161 Three Decades of NFCR Basic and Translational Research Funding to Primary Investigator Dr. Yung-Chi Cheng and Project Advances New Systems Biology Paradigm for Cancer Treatment…...
Lynparza® Approval Brings New Hope for Pancreatic Cancer Patients
Maintenance therapy previously approved for breast and ovarian cancer patients now shown to reduce the risk of disease progression or death by 47 percent among pancreatic cancer patients. Pancreatic cancer made headlines throughout 2019 after both Jeopardy! host Alex Trebek and U.S. Congressman John Lewis were diagnosed with the devastating…...
Strategic Media Partner
